BRPI0516314A - uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv - Google Patents

uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv

Info

Publication number
BRPI0516314A
BRPI0516314A BRPI0516314-5A BRPI0516314A BRPI0516314A BR PI0516314 A BRPI0516314 A BR PI0516314A BR PI0516314 A BRPI0516314 A BR PI0516314A BR PI0516314 A BRPI0516314 A BR PI0516314A
Authority
BR
Brazil
Prior art keywords
hiv
treatment
whole
infected individual
chronically infected
Prior art date
Application number
BRPI0516314-5A
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Wei-Lu
Original Assignee
Biovaxim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovaxim Ltd filed Critical Biovaxim Ltd
Publication of BRPI0516314A publication Critical patent/BRPI0516314A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

USO DE HIV INTEIRO E MéTODO DE TRATAMENTO DE UM INDIVìDUO CRONICAMENTE INFECTADO COM HIV. Um HIV inteiro inativado de um subtipo particular é utilizado para preparar vacinas e composições farmacêuticas que contêm vacinas. As vacinas podem ser usadas para tratar indivíduos cronicamente infectados com HIV, por indução de uma resposta imune celular protetora nos indivíduos contra o mesmo subtipo HIV usado para produzir a vacina.
BRPI0516314-5A 2004-10-04 2005-10-04 uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv BRPI0516314A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61572904P 2004-10-04 2004-10-04
PCT/IB2005/003384 WO2006038124A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
US11/243,094 US20060093623A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection

Publications (1)

Publication Number Publication Date
BRPI0516314A true BRPI0516314A (pt) 2008-09-02

Family

ID=35695555

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516314-5A BRPI0516314A (pt) 2004-10-04 2005-10-04 uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv

Country Status (14)

Country Link
US (1) US20060093623A1 (pt)
EP (1) EP1797175B1 (pt)
JP (1) JP2008515795A (pt)
CN (1) CN101056977B (pt)
AT (1) ATE401392T1 (pt)
AU (1) AU2005290930B2 (pt)
BR (1) BRPI0516314A (pt)
CA (1) CA2582426A1 (pt)
DE (1) DE602005008264D1 (pt)
ES (1) ES2310848T3 (pt)
IL (1) IL182440A (pt)
MX (1) MX2007004028A (pt)
RU (1) RU2396346C2 (pt)
WO (1) WO2006038124A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2213299B1 (fr) 2009-01-29 2015-09-09 Michel Vandevelde Composition vaccinale à base de virus exhibant une protéine à motif(s) en doigt de zinc, son procédé de préparation et son utilisation
US20100216120A1 (en) * 2009-02-23 2010-08-26 Candace Pert Rapid infectious virus assay
ES2606511T3 (es) * 2011-04-06 2017-03-24 Biovaxim Limited Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos
JP2015513401A (ja) * 2012-03-02 2015-05-14 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 樹状細胞ワクチンの調製方法
EP2821082A1 (en) * 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
AU2020298552A1 (en) * 2019-07-02 2022-03-03 Seattle Project Corp. HIV antigens and MHC complexes
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383806B1 (en) * 1998-02-13 2002-05-07 Adan Rios Method for the development of an HIV vaccine
US6828460B2 (en) * 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
JP2003523365A (ja) * 2000-01-28 2003-08-05 スタテンズ セーラム インスティテュート Ｈｉｖ感染の診断及びコントロールのためのｈｉｖペプチド及びそれをエンコードする核酸
US20040236093A1 (en) * 2001-02-27 2004-11-25 Olivier Schwartz Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
US20060239962A1 (en) * 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
US20050214318A1 (en) * 2003-10-23 2005-09-29 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on fusion protein

Also Published As

Publication number Publication date
ES2310848T3 (es) 2009-01-16
EP1797175A1 (en) 2007-06-20
MX2007004028A (es) 2007-09-11
IL182440A (en) 2011-01-31
AU2005290930A1 (en) 2006-04-13
IL182440A0 (en) 2007-07-24
CN101056977B (zh) 2013-01-30
RU2007115549A (ru) 2008-11-10
US20060093623A1 (en) 2006-05-04
WO2006038124A1 (en) 2006-04-13
RU2396346C2 (ru) 2010-08-10
DE602005008264D1 (de) 2008-08-28
ATE401392T1 (de) 2008-08-15
CN101056977A (zh) 2007-10-17
EP1797175B1 (en) 2008-07-16
CA2582426A1 (en) 2006-04-13
AU2005290930B2 (en) 2010-12-16
JP2008515795A (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
MX2018014573A (es) Vacuna contra el virus del zika.
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
CR20220082A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
BR112022022859A2 (pt) Vacinas contra sars-cov-2
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
CO2022008701A2 (es) Uso y composición farmacéutica de derivados de fenilisoxazolil metilen-naftaleno-éter
BR112022007253A2 (pt) Vacinas contra o vírus influenza e usos das mesmas
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
AR039982A1 (es) Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.